102 related articles for article (PubMed ID: 37382635)
1. De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.
Chakraborty S; Coleman C; Manoj P; Demircioglu D; Shah N; de Stanchina E; Rudin CM; Hasson D; Sen T
Clin Cancer Res; 2023 Sep; 29(17):3526-3540. PubMed ID: 37382635
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
[TBL] [Abstract][Full Text] [Related]
3. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
[TBL] [Abstract][Full Text] [Related]
4. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Ramkumar K; Tanimoto A; Della Corte CM; Stewart CA; Wang Q; Shen L; Cardnell RJ; Wang J; Polanska UM; Andersen C; Saeh J; Pease JE; Travers J; Fabbri G; Gay CM; Urosevic J; Byers LA
Clin Cancer Res; 2023 Aug; 29(16):3237-3249. PubMed ID: 37289191
[TBL] [Abstract][Full Text] [Related]
5. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Badin F
Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
[TBL] [Abstract][Full Text] [Related]
6. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
[TBL] [Abstract][Full Text] [Related]
7. Targeting PEA3 transcription factors to mitigate small cell lung cancer progression.
Shia DW; Choi W; Vijayaraj P; Vuong V; Sandlin JM; Lu MM; Aziz A; Marin C; Aros CJ; Sen C; Durra A; Lund AJ; Purkayastha A; Rickabaugh TM; Graeber TG; Gomperts BN
Oncogene; 2023 Feb; 42(6):434-448. PubMed ID: 36509998
[TBL] [Abstract][Full Text] [Related]
8. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract][Full Text] [Related]
9. A multiplexed in vivo approach to identify driver genes in small cell lung cancer.
Lee MC; Cai H; Murray CW; Li C; Shue YT; Andrejka L; He AL; Holzem AME; Drainas AP; Ko JH; Coles GL; Kong C; Zhu S; Zhu C; Wang J; van de Rijn M; Petrov DA; Winslow MM; Sage J
Cell Rep; 2023 Jan; 42(1):111990. PubMed ID: 36640300
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
11. A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer.
Thomas PL; Madubata CJ; Aldrich MC; Lee MM; Owonikoko TK; Minna JD; Rudin CM; Sage J; Lovly CM
Cancer Discov; 2021 Feb; 11(2):240-244. PubMed ID: 33318034
[TBL] [Abstract][Full Text] [Related]
12. Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer.
Wasifuddin M; Ilerhunmwuwa NP; Becerra H; Hakobyan N; Wasifuddin S; Asadi HA; Wang JC
J Chemother; 2024 Jan; ():1-6. PubMed ID: 38234179
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of BMC-PDC-019: a novel patient-derived cell line of EGFR-mutant pulmonary adenocarcinoma transformed into small-cell lung cancer.
Kim MY; Jung SY; Hong S; Oh SW; Jin KN; Kim JE; Kim JS
Hum Cell; 2023 Nov; 36(6):2179-2186. PubMed ID: 37707774
[TBL] [Abstract][Full Text] [Related]
14. AMPAR receptor inhibitors suppress proliferation of human small cell lung cancer cell lines.
Masumoto N; Kato S; Aichi M; Hasegawa S; Sahara K; Suyama K; Sano A; Miyazaki T; Okudela K; Kaneko T; Takahashi T
Thorac Cancer; 2023 Oct; 14(29):2897-2908. PubMed ID: 37605807
[TBL] [Abstract][Full Text] [Related]
15. Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy.
Kodama M; Toyokawa G; Sugahara O; Sugiyama S; Haratake N; Yamada Y; Wada R; Takamori S; Shimokawa M; Takenaka T; Tagawa T; Kittaka H; Tsuruda T; Tanaka K; Komatsu Y; Nakata K; Imado Y; Yamazaki K; Okamoto I; Oda Y; Takahashi M; Izumi Y; Bamba T; Shimizu H; Yoshizumi T; Nakayama KI
Cell Rep; 2023 Aug; 42(8):112899. PubMed ID: 37531252
[TBL] [Abstract][Full Text] [Related]
16. Unified tumor growth mechanisms from multimodel inference and dataset integration.
Beik SP; Harris LA; Kochen MA; Sage J; Quaranta V; Lopez CF
PLoS Comput Biol; 2023 Jul; 19(7):e1011215. PubMed ID: 37406008
[TBL] [Abstract][Full Text] [Related]
17. Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer.
Bhamidipati D; Subbiah V
Oncoscience; 2023; 10():22-23. PubMed ID: 37324544
[No Abstract] [Full Text] [Related]
18. Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Bassel LL; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2024 Mar; 16(3):664. PubMed ID: 38366163
[TBL] [Abstract][Full Text] [Related]
19. HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.
Jiang T; Jin Q; Wang J; Wu F; Chen J; Chen G; Huang Y; Chen J; Cheng Y; Wang Q; Pan Y; Zhou J; Shi J; Xu X; Lin L; Zhang W; Zhang Y; Liu Y; Fang Y; Feng J; Wang Z; Hu S; Fang J; Shu Y; Cui J; Hu Y; Yao W; Li X; Lin X; Wang R; Wang Y; Shi W; Feng G; Ni J; Mao B; Ren D; Sun H; Zhang H; Chen L; Zhou C; Ren S
Clin Cancer Res; 2023 Dec; 29(23):4830-4843. PubMed ID: 37449971
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
